4-guanidinobenzoate has been researched along with nafamostat in 4 studies
| Studies (4-guanidinobenzoate) | Trials (4-guanidinobenzoate) | Recent Studies (post-2010) (4-guanidinobenzoate) | Studies (nafamostat) | Trials (nafamostat) | Recent Studies (post-2010) (nafamostat) |
|---|---|---|---|---|---|
| 16 | 0 | 3 | 640 | 54 | 198 |
| Protein | Taxonomy | 4-guanidinobenzoate (IC50) | nafamostat (IC50) |
|---|---|---|---|
| Ubiquitin-like modifier activating enzyme 2 | Homo sapiens (human) | 7.47 | |
| SUMO1 activating enzyme subunit 1 | Homo sapiens (human) | 7.47 | |
| ubiquitin-like modifier-activating enzyme 1 | Homo sapiens (human) | 14 | |
| SUMO-conjugating enzyme UBC9 | Homo sapiens (human) | 7.47 | |
| ubiquitin-conjugating enzyme E2 N | Homo sapiens (human) | 14 | |
| ubiquitin-conjugating enzyme E2 variant 1 isoform a | Homo sapiens (human) | 14 | |
| Prothrombin | Homo sapiens (human) | 1.9 | |
| Complement C1r subcomponent | Homo sapiens (human) | 0.8 | |
| Plasminogen | Homo sapiens (human) | 2.9 | |
| Cationic trypsin | Bos taurus (cattle) | 0.017 | |
| Serine protease hepsin | Homo sapiens (human) | 0.005 | |
| Trypsin-1 | Homo sapiens (human) | 0.017 | |
| Complement C1s subcomponent | Homo sapiens (human) | 0.029 | |
| Hepatocyte growth factor activator | Homo sapiens (human) | 0.15 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asano, Y; Imai, M; Muto, S | 1 |
| Asano, Y; Furuya, H; Ookawara, S; Sakairi, Y; Sakurai, T; Tabei, K | 1 |
| Henderson, IM; McLoughlin, SB; Padova, A; Ramjee, MK | 1 |
| Adachi, M; Iwashita, K; Kitamura, K; Miyoshi, T; Nagano, J; Narikiyo, T; Nonoguchi, H; Shiraishi, N; Tomita, K; Tuyen, DG | 1 |
4 other study(ies) available for 4-guanidinobenzoate and nafamostat
| Article | Year |
|---|---|
Mechanisms of the hyperkalaemia caused by nafamostat mesilate: effects of its two metabolites on Na+ and K+ transport properties in the rabbit cortical collecting duct.
Topics: Animals; Benzamidines; Benzoates; Biological Transport, Active; Dose-Response Relationship, Drug; Electrophysiology; Female; Guanidines; Humans; Hyperkalemia; In Vitro Techniques; Infant, Newborn; Kidney Tubules, Collecting; Membrane Potentials; Microelectrodes; Naphthols; Phenobarbital; Potassium; Rabbits; Serine Proteinase Inhibitors; Sodium | 1994 |
Additional mechanisms of nafamostat mesilate-associated hyperkalaemia.
Topics: Adult; Benzamidines; Benzoates; Erythrocytes; Guanidines; Humans; Hyperkalemia; In Vitro Techniques; Naphthols; Potassium; Protease Inhibitors; Sodium-Potassium-Exchanging ATPase | 1996 |
The kinetic and structural characterization of the reaction of nafamostat with bovine pancreatic trypsin.
Topics: Animals; Anticoagulants; Benzamidines; Benzoates; Binding Sites; Cattle; Guanidines; Kinetics; Mass Spectrometry; Models, Chemical; Molecular Structure; Naphthols; Pancreas; Serine Proteinase Inhibitors; Spectrum Analysis; Substrate Specificity; Trypsin | 2000 |
Inhibition of prostasin secretion by serine protease inhibitors in the kidney.
Topics: Animals; Benzamidines; Benzoates; Cell Line, Transformed; Guanidines; Infusions, Intravenous; Kidney; Male; Mice; Naphthols; Protease Inhibitors; Rats; Rats, Sprague-Dawley; Serine Endopeptidases; Serine Proteinase Inhibitors | 2003 |